在转移性去势抵抗性前列腺癌中，除雄激素受体途径抑制剂外，PARP 抑制剂应仅限于 BRCA 突变携带者。
PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers.
发表日期：2024 Sep 03
作者：
Elena Castro
来源：
European Urology Focus
摘要：
对于肿瘤存在 BRCA1/2 改变的转移性去势抵抗性前列腺癌患者，将 PARP 抑制剂和雄激素受体途径抑制剂联合用于一线治疗的潜在益处超过了潜在的副作用。需要进一步的研究来确定没有可检测到的 BRCA1/2 缺陷的患者可以从这种方法中受益。版权所有 © 2024。由 Elsevier B.V. 出版。
For patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 alterations, the potential benefits of combining a PARP inhibitor and an androgen receptor pathway inhibitor for first-line treatment outweigh the potential side effects. Further research is required to identify patients without detectable BRCA1/2 defects who would benefit from this approach.Copyright © 2024. Published by Elsevier B.V.